Parker Institute scientists herald a cell therapy breakthrough in the lab, using next-gen CRISPR tech to engineer T cells
The two pioneering CAR-T therapies on the market — Kymriah and Yescarta — rely on viral vectors to complete the engineering work needed to make a cancer patient’s T cells into a therapy. But a group of Parker Institute for Cancer Immunotherapy-backed scientists at UCSF and UCLA say they have perfected a new approach using CRISPR gene editing tech that they believe will transform the field — opening the door to a range of cell therapies that can be built and manufactured far more easily than the first-gen crowd.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.